
What you need to know
- The Medical Devices Rules, 2017 took effect on 1 January 2018 and, since 2020, cover all medical devices sold in India.
- Class A and B manufacturing licences come from State Licensing Authorities; Class C and D licences and all imports come from the DCGI as Central Licensing Authority.
- Class A and B devices came under the licence regime from 1 October 2022 and Class C and D devices from 1 October 2023, CDSCO circulars say; non-sterile, non-measuring Class A devices need only registration.
- The rules set decision windows, including inspection of Class C and D sites within 60 days and import decisions within nine months.
- August 2026 amendments added a schedule of testing fees, sterilisation site labelling and EU approvals to the rule 63 clinical data waiver.
The Medical Device Rules, formally the Medical Devices Rules, 2017, decide who may make, import, test and sell a medical device in India, which regulator signs off and how long the regulator has to decide. For regulatory heads at manufacturers and importers, hospital procurement teams and investors, the questions are concrete: which risk class a product falls in, which form goes to which authority, what the Medical Device Rules say about audits, timelines and fees, and what changed in 2025 and 2026. This guide answers them from MDR 2017 itself and from documents published by the Central Drugs Standard Control Organisation (CDSCO), as of November 2026.
In this guide “MDR 2017” means the rules as amended. The text follows the version of the Medical Devices Rules that CDSCO lists on its Medical Devices Rules page under 15 February 2023, CDSCO’s FAQ document CDSCO/FAQ/MD/01/2024, and the amending notifications on its gazette page.
What the Medical Device Rules are and who enforces them
The Central Government notified the Medical Devices Rules, 2017 as G.S.R. 78(E) on 31 January 2017. Under rule 1(2) they “come into force with effect from 1st day of January, 2018”, unless a provision says otherwise. Their scope widened on 11 February 2020, when S.O. 648(E) brought all medical devices under MDR 2017, as CDSCO’s FAQ explains.
Two authorities share the work under the Medical Device Rules. The Central Licensing Authority is “the Drugs Controller General of India appointed by the Central Government” (rule 3(h)). A State Licensing Authority is the authority a state government designates under rule 8(2). According to the CDSCO FAQ, the central authority licenses the manufacture of Class C and Class D devices and handles all imports, clinical investigations and test licences; the state authority licenses the manufacture of Class A and Class B devices and the sale, stock and distribution of devices of every class.
The Medical Device Rules also run a testing system. CDSCO’s Medical Devices Rules page lists notifications designating Central Medical Device Testing Laboratories, Medical Device Testing Officers and Medical Device Officers, and a 2023 amendment to rules 18 and 19 for notifying state medical device testing laboratories. In 2026 MDR 2017 gained a fee schedule for that testing, covered below.
Risk classes A to D under MDR 2017
Rule 4 of the Medical Device Rules sorts devices into four classes using the parameters in the First Schedule: Part 1 for devices other than in vitro diagnostics, and Part 2 for in vitro diagnostic devices. The CDSCO FAQ describes them as low risk, Class A; low moderate risk, Class B; moderate high risk, Class C; and high risk, Class D. The Central Licensing Authority classifies devices according to intended use and the other parameters, and under rule 4(4) the classified list is published on the CDSCO website and may be amended.
| Class | Risk | Manufacturing licence from | Application and licence forms | Check before grant |
|---|---|---|---|---|
| A | Low | State Licensing Authority | MD-3, licence MD-5 (loan licence MD-4, MD-6) | None; notified body audit within 120 days of grant |
| A, non-sterile and non-measuring | Low | Registration only | Online registration | Exempt from the licence requirement since 14 October 2022, subject to registration |
| B | Low moderate | State Licensing Authority | MD-3, licence MD-5 (loan licence MD-4, MD-6) | Notified body audit within 90 days of application |
| C | Moderate high | Central Licensing Authority | MD-7, licence MD-9 (loan licence MD-8, MD-10) | Inspection by at least two Medical Device Officers within 60 days of application |
| D | High | Central Licensing Authority | MD-7, licence MD-9 (loan licence MD-8, MD-10) | As for Class C |
CDSCO’s medical device division page links to lists of risk classifications approved for devices, including a separate list for non-sterile, non-measuring Class A devices, and on 5 December 2025 CDSCO issued a circular on a new provision for risk classification on its online system for medical devices.

How the licence requirement was phased in
Before 2020 only devices notified one by one were regulated as drugs. CDSCO’s Medical Devices Rules page lists a 2005 notification on sterile medical devices and later notifications in December 2018 and February 2019 that brought four and then eight more devices within the definition of a drug. The 2020 changes to the Medical Device Rules replaced that list-based approach with a phased move for every device.
G.S.R. 102(E), the Medical Devices (Amendment) Rules, 2020, came into force on 1 April 2020. It created a registration chapter in which a manufacturer uploads company and site details, a product table, an ISO 13485 certificate and a signed undertaking to the “Online System for Medical Devices” established by CDSCO, and then shows the registration number on the label. Registration was “on voluntary basis for a period of eighteen months” and mandatory after that.
The same notification set the end of the exemption from licences: it would “cease after a period of thirty months” for Class A and Class B devices and “forty-two months” for Class C and Class D devices. CDSCO’s circulars give the resulting dates under the Medical Devices Rules.
A CDSCO circular of 30 September 2022 says Class A and B devices came under the licensing regime from 1 October 2022, and a circular of 12 October 2023 says all Class C and D devices did so from 1 October 2023. Both let existing importers and manufacturers that had already applied for a licence carry on for up to six months from the circular, or until their application was decided, whichever came first. For Class A and B devices the application had to be made on or before 30 September 2022.
One group was then taken out again. G.S.R. 777(E) of 14 October 2022, the Medical Devices (Sixth Amendment) Rules, 2022, added a chapter for non-sterile, non-measuring Class A devices. They must be registered through an online portal, and in return the Eighth Schedule exempts them, subject to that registration, from Chapters IV, VII, VIII and XI for manufacture and Chapters V, VII, VIII and XI for import; CDSCO’s title for the notification calls this exemption from the licensing regime.
In August 2026 G.S.R. 744(E) inserted the words “and Quality Management System” into rules 19H and 19J of that chapter, which CDSCO’s gazette list describes as quality management system requirements for these devices.
Getting a manufacturing licence under the Medical Device Rules
The CDSCO regulatory pathway document and the Medical Device Rules set out the route. In outline:
- Confirm the class against CDSCO’s published classification list under rule 4(4).
- Prepare the Fourth Schedule dossier of regulatory, legal and technical documents, including a Plant or Site Master File and a Device Master File.
- Bring the site into line with the Fifth Schedule. Rule 22(i) says “the manufacturing site shall comply with the requirements of the Quality Management System”.
- Apply online. CDSCO says “All applications shall be submitted through Medical Devices online portal”, at cdscomdonline.gov.in, with the National Single Window System (NSWS) also listed.
- For Class A, apply in Form MD-3 to the State Licensing Authority. Under rule 20(4) no audit is needed before grant, but a notified body must audit the site within 120 days of the licence being granted.
- For Class B, a notified body verifies conformance before grant. Rule 20(6) sets the audit within 90 days of the application, and a decision within twenty days of receiving the audit report.
- For Class C and D, apply in Form MD-7 to the Central Licensing Authority. Scrutiny is to finish within 45 days of online submission (rule 21(4)), the site is inspected within 60 days of the application by at least two Medical Device Officers (rule 23(1)), and the licence is granted in Form MD-9 within 45 days of the inspection report (rule 25(1)).
Before full production, a manufacturer can obtain a test licence in Form MD-13, on an application in Form MD-12, to make devices for testing, evaluation or clinical investigation. The pathway document says the manufacturer should make at least three batches to generate quality control data.
Import licences, test licences and clinical investigation
Under MDR 2017 every import, whatever the class, needs a licence from the Central Licensing Authority: application in Form MD-14, licence in Form MD-15. Under rule 36(1) the authority decides “within a period of nine months from the date of application”. Rule 36(3) lets it grant the licence without a clinical investigation where a free sale certificate has been issued by Australia, Canada, Japan, a European Union country, the United Kingdom or the United States. The United Kingdom was added by G.S.R. 174(E) of 4 March 2022.
Other forms cover narrower cases. A test licence for imports is sought in Form MD-16 and granted in MD-17. Permission for a clinical investigation is sought in MD-22 and granted in MD-23, and the pathway document says a clinical investigation is not mandatory for Class A. Government hospitals importing investigational devices use MD-18 and MD-19, and imports for personal use use MD-20 and MD-21, the FAQ says.
For a device with no predicate, rule 63 of the Medical Device Rules requires permission in Form MD-26 after a clinical investigation. Its fourth proviso says the results of a clinical investigation may not be required where the device is approved by the regulators of the United Kingdom, the United States, Australia, Canada or Japan and has been marketed there for at least two years. By G.S.R. 744(E), the Medical Devices (Third Amendment) Rules, 2026, dated 14 August 2026 and published in the Gazette on 19 August, the government inserted “or European Union countries” after Japan in that proviso.
In September 2025 CDSCO also added a separate provision for subsequent importers to its online system.

Notified bodies, the online portal and fees
Notified bodies carry out the MDR 2017 audits for lower-risk sites. Under rule 11, an applicant body is accredited by the National Accreditation Body, with the National Accreditation Board for Certification Bodies under the Quality Council of India named as the interim body. The Central Licensing Authority then registers it and issues a certificate in Form MD-2 (rule 13(6)).
Under the Medical Device Rules a registered body can audit Class A sites, other than non-sterile and non-measuring devices, and Class B sites; after at least two years’ experience it can apply to audit Class C and D sites (rule 13(4)). Manufacturers do not choose: the FAQ says the body “will be assigned by the concerned State Licensing Authority”.
CDSCO’s medical device division page links to its lists of approved notified bodies, approved testing laboratories and approved devices on the cdscomdonline.gov.in portal. Applications and periodic safety update reports are filed through that portal, according to CDSCO’s pathway document and a March 2024 circular.
Licence, import and registration fees are set in the Second Schedule to the Medical Devices Rules, 2017, in rupees except where dollars are specified. The FAQ says fees for Class A and B manufacturing licences are paid to the State Licensing Authority by challan or electronically. The table gives the main Medical Devices Rules fees from the consolidated text CDSCO lists, which runs to G.S.R. 777(E) of October 2022. The 2026 amendments to MDR 2017 read for this guide do not change them, but applicants should confirm the current schedule before filing.
| Licence or permission | Fee in the Second Schedule |
|---|---|
| Manufacturing licence, Class A (other than non-sterile, non-measuring) or Class B | Rs 5,000 per site plus Rs 500 per distinct device |
| Manufacturing licence, Class C or Class D | Rs 50,000 per site plus Rs 1,000 per distinct device |
| Import licence, Class A device other than in vitro diagnostic | USD 1,000 per site plus USD 50 per device |
| Import licence, Class B device other than in vitro diagnostic | USD 2,000 per site plus USD 1,000 per device |
| Import licence, Class A or B in vitro diagnostic | USD 1,000 per site plus USD 10 per device |
| Import licence, Class C or D device other than in vitro diagnostic | USD 3,000 per site plus USD 1,500 per device |
| Import licence, Class C or D in vitro diagnostic | USD 3,000 per site plus USD 500 per device |
| Retention fee for manufacturing and import licences, due within five years | The same per-site and per-device amounts as the licence |
| Inspection of an overseas manufacturing site | USD 6,000 |
| Permission to conduct a clinical investigation under rule 51(2)(a) or (b) | Rs 1,00,000 for each |
| Permission for a device with no predicate (rule 63) | Rs 50,000 |
| Registration of a notified body | Rs 25,000 |
| Registration certificate for sale of medical devices | Rs 3,000 |
Testing fees are new to the Medical Device Rules. G.S.R. 743(E), the Medical Devices (Second Amendment) Rules, 2026, dated 14 August 2026 and published in the Gazette of India on 19 August 2026, added a Ninth Schedule of fees for test or evaluation and amended rule 19 to say “The fees for test or evaluation shall be those specified in ninth Schedule”. Fees not listed are set by the Director or Medical Device Testing Officer, and the prescribed costs rise by 5% each year. Examples:
| Test or product | Fee in the Ninth Schedule |
|---|---|
| Implantation test | Rs 5,000 |
| Sterility test | Rs 2,000 |
| Bacterial endotoxin test | Rs 3,000 qualitative, Rs 4,500 quantitative |
| Surgical sutures | Rs 3,000 |
| Condoms | Rs 2,500 |
| Intrauterine devices | Rs 2,500 |
| Surgical dressings | Rs 1,000 |
| Syringes and needles | Rs 1,000 |
Licence validity, changes and post-market duties
A licence under the Medical Device Rules does not expire in the ordinary way. Rule 29(1) says it “shall remain valid in perpetuity, subject to payment of licence retention fee”, which falls due before five years from issue. Rule 29(2) adds a late fee of 2% a month for up to 180 days, after which the licence is cancelled. The FAQ confirms that licences and registrations remain valid until suspended or cancelled. Rule 30 sets out suspension and cancellation of manufacturing licences, and rule 43A, inserted by G.S.R. 356(E) of 18 May 2022, does the same for import licences.
- The FAQ gives timelines of 45 days for major post-approval changes to manufacturing licences and 60 days for import licences.
- Minor changes need no prior approval but must be reported “within a period of 30 days after the change takes place”, the FAQ says.
- A change in the constitution of the licence holder must be reported within 45 days, with a fresh application within 180 days.
- Labels must carry the required particulars, including device name, manufacturer details, batch number and manufacturing licence number, “printed in indelible ink” (rule 44).
- Where sterilisation is outsourced to another licensed site, G.S.R. 743(E) requires the sterilisation site’s manufacturing licence number on the label, with a prefix such as “Ster. Mfg. Lic. No.”, mandatory six months from the notification.
- Rule 46 requires devices to bear a unique device identification from a date the Central Government specifies by order; G.S.R. 918(E) of 31 December 2021 amended that rule.
- Licence holders report adverse events under the Materiovigilance Programme of India and file periodic safety update reports through the portal, under CDSCO circulars of May 2024 and March 2024.
Sale is regulated under MDR 2017 too. G.S.R. 754(E) of 30 September 2022 brought in registration of premises for selling medical devices, using Forms MD-41 and MD-42; the FAQ says the registration in MD-42 is to be granted “within ten days from the date the application” is made. Since April 2025 CDSCO’s portal has generated market standing and non-conviction certificates automatically for licensed devices, according to a circular of 9 April 2025.
Recent amendments to the Medical Device Rules
The table lists the main changes to the Medical Device Rules since the 2020 overhaul, using the titles on CDSCO’s gazette notifications page and its Medical Devices Rules page. Drafts are marked; a draft has no legal effect until a final notification follows.
| Date | Notification | What it does |
|---|---|---|
| 11 February 2020 | G.S.R. 102(E) | Registration of all devices and phased licence requirement, in force 1 April 2020 |
| 31 December 2021 | G.S.R. 918(E) | Amends rule 46 on unique device identification |
| 4 March 2022 | G.S.R. 174(E) | Adds the United Kingdom to rule 36(3) |
| 18 May 2022 | G.S.R. 356(E) | Inserts rule 43A on suspension and cancellation |
| 30 September 2022 | G.S.R. 754(E) | Regulates sale through registration of premises |
| 14 October 2022 | G.S.R. 777(E) | Exempts non-sterile, non-measuring Class A devices from the licence requirement, subject to registration |
| 2 June 2023 | G.S.R. 409(E) | Amends rules 18 and 19 for notifying state testing laboratories |
| 4 December 2025 | G.S.R. 883(E), draft | Amendment in the Medical Devices Rules, 2017 |
| 2 March 2026 | G.S.R. 165(E) | Adds qualifications for medical device inspectors and government analysts |
| 10 April 2026 | G.S.R. 269(E) and 270(E), drafts | Medical device testing fee; provisions relating to the European Union; both finalised in August 2026 |
| 23 June 2026 | G.S.R. 515(E), draft | Further amendments to MDR 2017 |
| 14 August 2026 | G.S.R. 743(E) | Ninth Schedule testing fees; sterilisation site labelling; finalises draft G.S.R. 270(E) |
| 14 August 2026 | G.S.R. 744(E) | European Union countries added to rule 63; quality management system wording in rules 19H and 19J; finalises draft G.S.R. 269(E) |
Circulars have filled in the detail of how the Medical Device Rules work in practice. The CDSCO circulars page lists, among others, an April 2025 circular adding tooltips for legal forms on the SUGAM and medical device portals, the September 2025 provision for subsequent importers, a November 2025 circular on the need for a CDSCO or state licence when procurement agencies buy medical devices, the December 2025 risk classification provision, and a March 2026 circular on devices used for in vitro fertilisation.

What MDR 2017 means for manufacturers, importers and hospital buyers
For hospital and government buyers, the November 2025 procurement circular makes the MDR 2017 licence the first document to check: whether the device is covered by a licence from CDSCO or the relevant State Licensing Authority, for the right class and site. Because licences are perpetual, buyers can also ask whether the retention fee has been paid within the five-year cycle.
For importers, the August 2026 change matters most, alongside fees that the Second Schedule sets in dollars, from USD 1,000 to USD 3,000 per overseas site plus a charge for each device. A device approved by an EU regulator and marketed there for two years can now rely on the rule 63 proviso in the same way as one approved in the United Kingdom, the United States, Australia, Canada or Japan. The nine-month decision period under rule 36(1) is the outer limit to plan around. For UK-facing suppliers, The Healthcare Daily has reported on the MHRA’s annual device registration fees.
For domestic manufacturers, the 2026 amendments to the Medical Device Rules add costs and paperwork at the margin: published testing fees that rise 5% a year, a labelling change for those that outsource sterilisation, and quality management system wording for registered Class A products. The policy push towards local manufacturing continues, with ICMR picking seven institutes to develop priority devices and land for new plants, such as the 50 acres in Haldia that Truevis says West Bengal has allotted it. Indian device makers are profiled in The Healthcare Daily’s Suppliers Guide.
For investors, MDR 2017 status is a diligence item: the class of each product, whether each site holds the right licence, notified body audit history for Class A and B sites, and post-market reporting. A Class C or D product carries the longer central route, with inspection by Medical Device Officers, while Class A and B products depend on state authorities and notified bodies.
What to watch next
- The sterilisation labelling rule in G.S.R. 743(E), which becomes mandatory six months after the 14 August 2026 notification.
- Final versions of the draft amendments G.S.R. 883(E) and 515(E), published in December 2025 and June 2026; the April 2026 drafts have already become G.S.R. 743(E) and 744(E).
- How the State Licensing Authorities and notified bodies apply the new Medical Device Rules quality management system wording to registered Class A devices.
- Further changes to the MDR 2017 online system, after the 2025 provisions for subsequent importers and risk classification.
- Procurement practice, as agencies apply the November 2025 circular on licences in device tenders.
The Healthcare Daily covers device regulation in its MedTech and diagnostics section and tracks rule changes on The Tracker.
Questions readers ask
What are the Medical Device Rules 2017 in India?
The Medical Devices Rules, 2017 are India's rules for the manufacture, import, clinical investigation, testing and sale of medical devices. They were notified as G.S.R. 78(E) on 31 January 2017 and came into force on 1 January 2018. Since a February 2020 notification they apply to all medical devices, not only notified ones.
What are the risk classes of medical devices in India?
Rule 4 places devices in four classes using the First Schedule: Class A low risk, Class B low moderate risk, Class C moderate high risk and Class D high risk. The Central Licensing Authority classifies devices by intended use and other parameters, and CDSCO publishes the classification list on its website.
Who issues a medical device manufacturing licence in India?
State Licensing Authorities issue manufacturing licences for Class A and Class B devices on Form MD-3, with the licence in Form MD-5. The Central Licensing Authority, the Drugs Controller General of India, issues licences for Class C and Class D devices on Form MD-7, with the licence in Form MD-9.
How long does a medical device import licence take in India?
Rule 36 of the Medical Devices Rules, 2017 says the Central Licensing Authority decides an import application in Form MD-14 within nine months of the date of application. Where a free sale certificate exists from Australia, Canada, Japan, the European Union, the United Kingdom or the United States, the licence can be granted without a clinical investigation.
Do Class A medical devices need a licence in India?
Most Class A devices need a manufacturing licence from the State Licensing Authority, compulsory since 1 October 2022 according to CDSCO, granted without a prior audit but followed by a notified body audit within 120 days. Since 14 October 2022, non-sterile and non-measuring Class A devices are exempt from the licence requirement, provided they are registered on the online portal.
Is a medical device licence valid for life in India?
Under rule 29 a licence remains valid in perpetuity, subject to payment of a licence retention fee before five years from issue. A late fee of 2% a month applies for up to 180 days, after which the licence is deemed cancelled. Manufacturing licences can be suspended or cancelled under rule 30 and import licences under rule 43A.
What changed in the Medical Device Rules in 2026?
Two final amendments dated 14 August 2026 and published in the Gazette on 19 August added a Ninth Schedule of fees for testing and evaluation, a labelling rule for outsourced sterilisation, European Union approvals to the rule 63 clinical data waiver, and quality management system wording for registered Class A devices. They finalised the April 2026 drafts; drafts of December 2025 and June 2026 were still pending.
Sources
Announced plans, figures and dates are as stated in the sources below at the time of publication and can change. Conclusions drawn from them are our reading.
- CDSCO: Medical Devices Rules, 2017 (G.S.R. 78(E) dated 31 January 2017) (PDF)
- CDSCO: Medical Devices Rules, 2017, consolidated to G.S.R. 777(E), version listed under 15 February 2023 (PDF, rules and Second Schedule read)
- CDSCO: Acts and rules, Medical Devices Rules, 2017 page (list of amendments and notifications)
- CDSCO: FAQ on Medical Devices Rules, 2017 (CDSCO/FAQ/MD/01/2024) (PDF)
- CDSCO: Circular, Regulation of all Class A and B medical devices under licensing regime w.e.f. 01.10.2022 (PDF, 30 September 2022)
- CDSCO: Circular, Regulation of all Class C and D medical devices under licensing regime w.e.f. 01.10.2023 (PDF, scanned, 12 October 2023)
- CDSCO: Regulatory pathway under MDR-2017 (PDF)
- CDSCO: Medical device division page (approved lists, forms, guidance)
- CDSCO: G.S.R. 102(E), Medical Devices (Amendment) Rules, 2020 (PDF, 11 February 2020)
- CDSCO: G.S.R. 777(E), Medical Devices (Sixth Amendment) Rules, 2022 (PDF, 14 October 2022)
- CDSCO: G.S.R. 743(E), Medical Devices (Second Amendment) Rules, 2026 (PDF, 14 August 2026)
- CDSCO: G.S.R. 744(E), Medical Devices (Third Amendment) Rules, 2026 (PDF, 14 August 2026)
- CDSCO: Gazette notifications (Accessed November 2026)
- CDSCO: Circulars (Accessed November 2026)
Follow The Healthcare Daily on Google News
New stories appear where you already read the news.
The Healthcare Daily. We report from primary sources and list them on every story.


